Limits on physician access for reps continue to tighten
Latest SK&A survey finds more requirements for appointments, and more ‘no-see’ offices
The latest compilation of the regularly updated Office-Based Physician database of Irvine, CA-based SK&A indicates that 38.5% of U.S. physicians now require appointments to see them, up from 31.4% in the first half of 2008. The percentage of physicians who have banned sales-rep access altogether now stands at 23.6%, up 1.3% from the previous period. At hospital-owned medical practices, 31.2% have a “no-see” policy, and 44.6% require appointments. Access to physicians varies by region, with physicians practicing in the Southern U.S. being the most accessible and the Western U.S. being the least.
SK&A performs a telephone-based survey of practices and healthcare practitioners continuously, and compiles the data semiannually, as part of its database services for life sciences marketers, and custom reports.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
